Results 61 to 70 of about 7,404 (210)

Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. [PDF]

PLoS ONE, 2017
Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk in BRCA1/2 mutation carriers. Premenopausal RRSO is hypothesized to increase fracture risk more than natural menopause.
Ingrid E Fakkert, Eveline van der Veer, Elske Marije Abma, Joop D Lefrandt, Bruce H R Wolffenbuttel, Jan C Oosterwijk, Riemer H J A Slart, Iris G Westrik, Geertruida H de Bock, Marian J E Mourits   +9 more
doaj   +1 more source

Ovarian cancer [PDF]

, 2016
Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments.
A Bashashati, A Cassidy, A du Bois, A du Bois, A du Bois, A du Bois, A Gadducci, A Gnanasakthy, A Jemal, A Koushik, A Sokalska, A Varga, A Vazquez, A-M Patch, AA Ahmed, AA Tone, AD Santin, AJ Oswald, AL Jackson, AM Oza, AM Oza, AM Poveda, APM Finch, AR Mayer, B Kaufman, B Trabert, BA Goff, BA Goff, BE Howitt, BJ Monk, BJ Monk, BM Norquist, C Aghajanian, C Della Pepa, C Engel, C Lu, C Tian, CB Powell, CF Cheok, CJ Paller, CL Park, CL Pearce, CL Scott, CM Nagle, CM Olsen, Collaborative Group On Epidemiological Studies Of Ovarian Cancer, CP Crum, D Bell, D Callegaro-Filho, D Etemadmoghadam, D Hanahan, D Parkin, D Yang, DF Cella, DG Mutch, DK Armstrong, DM Eccles, DSP Tan, DW Kindelberger, E Basch, E Maritschnegg, E Pujade-Lauraine, E Pujade-Lauraine, E Zsiros, EA Calhoun, EMJJ Berns, F Medeiros, FS Hodi, G Coukos, G Ferrandina, G Liu, G Mangili, G Pentheroudakis, GJ Rustin, GJS Rustin, GL Ryland, H Falconer, H Kobayashi, HP Yang, I Hellström, I Romero, I Vergote, IA McNeish, IJ Jacobs, IJ Jacobs, J Brown, J Farley, J Hamanishi, J Kotsopoulos, J Ledermann, J Ledermann, J Liu, J Pfisterer, J Prat, J Walker, J Xie, JA Ledermann, JF Liu, JF Liu, JK Chan, JK Chan, JL Walker, JM Reyes-González, JN Bottsford-Miller, JN McAlpine, JS Hildebrand, JS Kwon, JW Carlson, K Alsop, K Basen-Engquist, K Gaitskell, K Schlienger, KA Donovan, KA Gelmon, KA Lowe, KC Wiegand, KL Bolton, KL Terry, KN Moore, KP Pennington, L McGowan, L Mei, L Wenzel, L Witkowski, L Wu, L Zhang, LH Castilla, LJ Havrilesky, LJ Havrilesky, LJ Havrilesky, LS Mørch, M Markman, M Markman, M Markman, M Sant, MA Bookman, MA Crispens, MA Merritt, MC Castells, MG Baratta, ML Disis, MR Stockler, MS Glickman, MS Piver, MS Piver, MS Rice, MW Audeh, N Katsumata, N Katsumata, N Keum, N Musrap, N Singh, N Suwaki, NR Gómez-Hidalgo, NS Horowitz, P Harter, P Jelinic, P-L Sung, PA Vasey, PG Moorman, PJ O'Donovan, R Perets, R Prakash, R Salani, RA Burger, RA Cannioto, RA Eeles, RD Alvarez, RE Bristow, RF Ozols, RGW Verhaak, RH Demir, RJ Kurman, RJ Kurman, RL Coleman, RL Siegel, RS Groen, RT Morris, RW Tothill, S Bentink, S Kehoe, S Mahner, S Pignata, S Pignata, S Zhang, S-J Baek, S-J Chang, S-J Chang, SA Cannistra, SA Narod, SC Houghton, SE Jensen, SK Sandhu, SM Domchek, SS Bassuk, SS Buys, T Al Rawahi, T Huang, T Walsh, TA Yap, TJ Herzog, TJ Herzog, TJ Perren, TM Friebel, TR Rebbeck, U Matulonis, U Menon, UA Matulonis, UA Matulonis, UA Matulonis, V Galic, V Jenkins, W Sakai, W-T Hwang, WA Cliby, WP McGuire, X Yang, Y Lee, Y Liu, Z Ketabi   +219 more
core   +1 more source

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma

International Journal of Cancer, EarlyView.
What's New? Ovarian clear cell carcinoma is highly associated with hypoxia. Hypoxia‐inducible factor 2A (HIF2A) is a key regulator of hypoxic responses, but its role in ovarian clear cell carcinoma remains unclear. This study demonstrated the unfavorable prognostic significance of HIF2A expression in ovarian clear cell carcinoma.
Mengxin Jiang, Ken Yamaguchi, Kohei Hamada, Yuko Hosoe, Yuka Mise, Sachiko Kitamura, Zhihong Liu, Hairong Wei, Zhenhai Gao, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Rin Mizuno, Taito Miyamoto, Junzo Hamanishi, Masaki Mandai   +15 more
wiley   +1 more source

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic [PDF]

, 2007
Background BRCA1/2 mutation carriers and women from a hereditary breast(/ovarian) cancer family have a highly increased risk of developing breast cancer (BC). Prophylactic mastectomy (PM) results in the greatest BC risk reduction.
Bernadette A. M. Heemskerk-Gerritsen, Cecile T. M. Brekelmans, Marian B. E. Menke-Pluymers, Albert N. van Geel, Madeleine M. A. Tilanus-Linthorst, Carina C. M. Bartels, Murly Tan, Hanne E. J. Meijers-Heijboer, Jan G. M. Klijn, Caroline Seynaeve, MC King, D Ford, JP Struewing, K Bergfeldt, H Meijers-Heijboer, TR Rebbeck, LC Hartmann, LC Hartmann, PA Meeuwissen, B Rosen, AN Geel van, EJ Meijers-Heijboer, H Meijers-Heijboer, CM Contant, PJ Bresser, LC Verhoog, LC Verhoog, LC Verhoog, D Ford, K Metcalfe, M Robson, LC Verhoog, K Shahedi, YM Kirova, MM Tilanus-Linthorst, CI Scott, KK Khurana, N Hoogerbrugge, M Kriege, CK Kuhl, JC Boughey, CM Contant, KY Lin, SM Zion   +43 more
core   +2 more sources

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. [PDF]

, 2015
This is a freely-available open access publication. Please cite the published version which is available via the DOI link in this record.BACKGROUND: Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by mutations in the DNA ...
Coelho, H, Cooper, Chris, Frayling, I, Hoyle, M, Huxley, N, Hyde, C, Jones-Hughes, T, Snowsill, T   +7 more
core   +2 more sources

Pelvic venous disorders in women: Diagnosis and management for gynecologists

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Pelvic venous disorders (PeVD) are an underrecognized yet significant cause of chronic pelvic pain (CPP) in reproductive‐aged women, characterized by venous reflux, obstruction, or both. This clinical opinion provides a practical overview of PeVD for gynecologists, outlining its pathophysiology, common presentations, diagnostic approach, and ...
Tiffany Ni, Inbar Friedman, Jessica Smith, Brian Liu, Mary Melchior, Andrew D. Brown   +5 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

“It was a no-brainer”: A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy

Gynecologic Oncology Reports, 2022
Objective: Previvors are becoming more aware of the option of risk-reducing salpingectomy with delayed oophorectomy (RRS-DO) to mitigate their risk of ovarian cancer.
Caroline Gellman, Charlotte Ezratty, Julia Schwarz, Valentin Kolev, Stephanie V. Blank   +4 more
doaj   +1 more source

Association Between Preoperative Dyslipidemia and the Prognosis of Patients With Endometrial Cancer: A Retrospective Cohort Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Endometrial cancer (EC) is closely related to metabolic disorders. We aimed to investigate whether preoperative dyslipidemia independently affects the prognosis of patients with EC. One hundred and ninety‐four women diagnosed with EC by pathology and who had undergone standardized surgical treatment at the Affiliated Hospital of Jining Medical
Song Li, Rong‐He Sun, Qing Chen, Zeng‐Shu Huang, Yun‐Fei Wang, Chang‐Zhong Li   +5 more
wiley   +1 more source